Loading
Led SPEARHEAD-1, the trial that made afami-cel the first engineered TCR T-cell therapy approved for a solid tumour.
Sandra D'Angelo was principal investigator of SPEARHEAD-1, which showed the MAGE-A4-directed TCR T-cell therapy afamitresgene autoleucel produces durable responses in synovial sarcoma and led to its 2024 approval, the first engineered T-cell therapy for a solid tumour. She also led the JAVELIN Merkel 200 trial that won avelumab approval in Merkel cell carcinoma and leads cellular therapy trials in sarcoma at MSKCC.
Shares MAGE-A4, Afamitresgene autoleucel, SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, TCR-T cell therapy.
Shares Afamitresgene autoleucel, SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
Shares Afamitresgene autoleucel, TCR-T cell therapy, Sarcomas (soft tissue, bone, GIST).
Shares Memorial Sloan Kettering Cancer Center, Sarcomas (soft tissue, bone, GIST) and the tag sarcoma.
Shares TCR-T cell therapy and the tag tcr-t.
Shares MAGE-A4, TCR-T cell therapy.
Shares Sarcomas (soft tissue, bone, GIST) and the tag sarcoma.